AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032
AbbVie (NYSE:ABBV) today announced that it expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion